MGRM

[poorman1]

MGRM - Monogram Biosciences

To me, it appears that strong support has been tested at $1.47 and is starting to go up again.  The market cap is pretty high $204MM, however they have $70MM in cash.

Below is a 6 month and 2 year chart.  Worth a look.

[Leaira]

Nice pick!  It looks like the RSI is just coming out of oversold conditions, and the MACD is crossing over to positive divergence.  I'll keep it on my watch list, and might get some of it on Monday if it still looks strong.

Leaira

[Terliso]

MGRM Breaking the decending trendline with increasing volume

(applaud poorman)

[setravis]

Nice pick  poorman1.......Applaud
News that was out on 01 December

Press Release Source: Monogram Biosciences, Inc.


Monogram's eTag(TM) Technology Featured in British Journal of Cancer
Thursday December 1, 7:00 am ET 
Novel Dimerization Assay Illuminates Key Molecular Differences That Contribute to Side Effects Among Targeted Therapies


SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., formerly ViroLogic, Inc., (Nasdaq: MGRM - News) announced the publication in the British Journal of Cancer, a Nature Publishing Group journal, of a study demonstrating the potential of the company's eTag(TM) technology to assess the activation of specific signal transduction pathways in patient samples. The paper reports a study of correlations between skin toxicity, a common side effect of certain targeted cancer therapies but not others, and the dimerization status of EGFR and HER2 proteins present in skin. The study, presented by researchers from the Cedars-Sinai Medical Center, illustrates how the eTag technology's ability to identify and quantitate EGFR dimerization can be used to understand drug effects.


"Monogram's eTag technology is able to identify protein dimerization status in clinical tissue," said co-author David Agus, MD, Research Director at the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and senior author of the study. "The eTag assay is both highly sensitive and quantitative, and these attributes make it a very promising clinical tool for identifying critical protein markers that may be indicative of patient response to therapies."

The study showed that EGFR homodimers are the predominant form of dimer present in normal keratinocytes, and that inhibition of EGFR homodimerization by certain drugs that target EGFR correlates with skin toxicity, whereas drugs that target HER2 may not lead to similar skin toxicity because EGFR/HER2 heterodimers are absent in normal skin. This provides a plausible explanation for the observation that skin toxicity is associated with drugs that target EGFR but not with those that target HER2.

"For Monogram, this study is important because it represents an important step in establishing scientific validation of our eTag technology in a peer- reviewed setting," said Michael Bates, MD, Monogram's Vice President of Clinical Research. "Additional studies are underway with a number of collaborators to demonstrate the ability of eTag assays to predict responsiveness of individual patients to certain targeted cancer therapies."

About the eTag System

Monogram's eTag assays enable detailed analysis of protein drug targets and signaling pathways in cancer cells, using tissue lysates or FFPE specimens, which is the standard format in most pathology labs. The assays can provide information on a drug's mechanism of action, selectivity and potency in a biological setting in pre-clinical research, and enable selection of clinical trial populations later in a drug's development. In addition, Monogram believes these assays may ultimately be used to help physicians better determine whether certain therapies are more appropriate for individual cancer patients, and whether to combine therapies with different mechanisms or properties. The first commercially available activated receptor test panel based on eTag technology, focused on the EGFR/HER receptor family, is planned to be introduced in 2006.

About Monogram Biosciences, Inc.

Monogram, formerly ViroLogic, Inc., is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

eTag(TM) is a trademark of Monogram Biosciences, Inc.

FORWARD LOOKING STATEMENTS

Certain statements in this press release are forward-looking, including statements regarding the ability of assays based on the eTag technology to predict individual patient response to targeted cancer therapies. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to the performance of our products; whether measurement of dimerization or protein pathway activation are key indicators in determining individual patient response; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; whether the results of studies conducted with patient samples treated with a particular targeted cancer therapy will be representative of results with other targeted therapies; whether clinical data derived from these studies will be adequate to support the commercial introduction of a test for patient responsiveness to targeted cancer therapies; the timing and launch of eTag assays for patient use; our ability to establish reliable, high-volume operations at commercially reasonable costs; the development of competitive technologies; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the timing and ultimate size of pharmaceutical company clinical trials; whether payors will authorize reimbursement for its products; whether the FDA or any other agency will decide to regulate Monogram's products or services; whether the Company will encounter problems or delays in automating its processes; whether licenses to third party technology will be available; whether Monogram is able to build brand loyalty and expand revenues; the potential impact of cash and or stock payments by us on the Contingent Value Rights issued to shareholders of ACLARA; and whether Monogram will be able to raise sufficient capital when required. For a discussion of other factors that may cause Monogram's actual events to differ from those projected, please refer to the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.


    Contacts:
     Alfred G. Merriweather                Jeremiah Hall
     Chief Financial Officer               Feinstein Kean Healthcare
     Tel: 650 624-4576                     Tel: 415 677-2700
     [email protected]         [email protected]
--------------------------------------------------------------------------------
Source: Monogram Biosciences, Inc.

[REALDEALS21]

MGRM is HOT today, alot of news to run off of !!! HUGE VOLUME !

Pfizer to Invest $25 Million in Monogram
Monday May 8, 8:00 am ET
Collaboration to Secure Worldwide Availability of Monogram's Co-Receptor Tropism Assay

SOUTH SAN FRANCISCO, Calif., May 8 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM - News) today announced that Pfizer, Inc (NYSE: PFE - News) has agreed to invest $25 million in Monogram and has entered into a worldwide non-exclusive collaboration agreement for Monogram's Co-Receptor Tropism Assay.

ADVERTISEMENT
click here
Under the terms of the agreements, Pfizer will invest $25 million in Monogram through a 3% Senior Secured Convertible Note, payable in May 2010. The investment, which is subject to customary closing conditions, is expected to close this month.

Separately today, Pfizer and Monogram jointly announced the signing of a Collaboration Agreement in order to make Monogram's Co-Receptor Tropism Assay available for patient use on a global basis. The Co-Receptor Tropism Assay has been utilized in HIV/AIDS clinical trials for Pfizer's investigational CCR5 inhibitor drug candidate, maraviroc.

"Monogram and Pfizer have had an outstanding business relationship for a number of years," said William D. Young, Monogram CEO. "In 2002, Pfizer made an equity investment in Monogram and since that time, we have provided sophisticated molecular diagnostic testing services and scientific assistance in the area of HIV drug resistance for many of Pfizer's HIV programs, including the ongoing Phase III maraviroc clinical development program. We are now delighted to be significantly extending that relationship through Pfizer's investment of additional capital and through a collaboration to make our Co-Receptor Tropism Assay available globally.

"Pfizer's $25 million investment is expected to provide significantly greater financial flexibility to Monogram," said Alfred G. Merriweather, Monogram's Chief Financial Officer. "At the end of the first quarter of 2006, we had $67 million in cash and investments. On a proforma basis, including the anticipated proceeds of Pfizer's investment, these cash resources would be $92 million. This strengthening of our balance sheet gives us enhanced flexibility to address our business and financial opportunities and to facilitate Monogram's continued growth and development."

Convertible Note Financing

Pfizer will invest $25 million in Monogram through a Senior Secured Convertible Note. The note will bear interest at 3%, payable quarterly in cash, or at Monogram's option, in Monogram Common Stock, subject to certain limitations. The Note will be issued on May 19, 2006, subject to the satisfaction of customary closing conditions, and will be due on May 19, 2010, unless converted earlier. The Note will be convertible at Pfizer's option into Monogram Common Stock at a conversion price, which shall be initially set at a 20% premium to the average closing price of Monogram Common Stock during a specified period prior to the issuance of the Note. Monogram is obligated to file a registration statement for the estimated number of shares of Common Stock underlying the Note within thirty days of issuance of the Note. After this registration statement is effective, the Note will automatically convert at any time should the closing price of Monogram's Common Stock be greater than 150% of the conversion price for twenty out of thirty consecutive trading days. The Note will be secured by all assets related to Monogram's HIV testing business, will be subject to certain covenants by Monogram and will be senior in right of payment to all existing and future indebtedness, subject to certain limited exceptions.

Collaboration Agreement

The collaboration agreement is for the period through December 31, 2009 and is renewable by Pfizer for five successive one-year terms. Under the agreement, Pfizer and Monogram will collaborate to make Monogram's Co-Receptor Tropism Assay available globally. Monogram will take the lead in commercialization of the Co-Receptor Tropism Assay in the United States and Pfizer will take the lead internationally.



Pfizer and Monogram to Make HIV Co-Receptor Tropism Assay Available Globally
Monday May 8, 8:00 am ET
Understanding HIV's Co-Receptor Usage May Facilitate Targeting of Drugs to Appropriate Patients

NEW YORK and SOUTH SAN FRANCISCO, Calif., May 8 /PRNewswire-FirstCall/ -- Pfizer Inc (NYSE: PFE - News) and Monogram Biosciences, Inc. (Nasdaq: MGRM - News) announced today a non-exclusive collaboration to make Monogram's HIV Co-Receptor Tropism Assay available for patient use on a global basis. The assay is a diagnostic tool to show tropism -- the path taken by the virus to access human CD4 cells.

ADVERTISEMENT
Tropism information is intended to help identify patients who are most likely to respond to a class of investigational drugs known as CCR5 antagonists. CCR5 antagonists are designed to block viral cell entry through the CCR5 co-receptor. Studies have shown that 80-85 percent of people newly diagnosed with HIV and previously untreated with HIV therapy have dominant CCR5-tropic virus. This drops to 50-60 percent in patients who have been treated before with anti-retroviral medicines.

Pfizer has a CCR5 antagonist, maraviroc, in phase 3 development and has used the Monogram tropism assay to select patients for enrollment in late- stage clinical studies. The agreement announced today expands this clinical trial collaboration and provides for global availability of Monogram's assay in a multi-year collaboration.

"Because of the important role the Co-Receptor Tropism Assay is believed to play in CCR5 antagonist clinical development, we are pleased to be expanding our partnership with Pfizer. We look forward to working together so that the right medicine can be made available to the right patients at the right time," said William D. Young, Monogram CEO.

Under the terms of the agreement announced today, Pfizer and Monogram will collaborate to make Monogram's Co-Receptor Tropism Assay available globally. Pfizer also entered into an agreement to invest $25 million in Monogram this month through a Senior Secured Convertible Note, payable in May 2010. The closing of the investment is subject to customary closing conditions.

"CCR5 antagonists have a mechanism of action different from currently approved drugs," said John LaMattina, president, Pfizer Global Research and Development. "With this collaboration we are working to advance global access to new diagnostics that may better assess the potential for CCR5 antagonists to fulfill an unmet medical need."



Monogram Biosciences  Q1 loss narrows
Mon May 8, 2006 8:59 AM ET

[wrangler]

MGRM : testing 200 MA

[nica33]

Huge volume today... Any FDA announcement?  Buy the rumor??